NEK7诱导的EGFR丝氨酸1070位点磷酸化驱动肝细胞癌获得性仑伐替尼耐药
研究建立获得性仑伐替尼耐药的肝细胞癌类器官和细胞系,通过激酶CRISPR-Cas9遗传筛选鉴定NEK7为耐药基因。NEK7结合EGFR并使其丝氨酸1070位点磷酸化,激活MAPK和PI3K/AKT通路;靶向氨基酸979至1099结构域的抑制肽可抑制该磷酸化并抑制耐药肿瘤活性。
要点
- NEK7被鉴定为肝细胞癌获得性仑伐替尼耐药基因。
- NEK7结合EGFR并磷酸化其丝氨酸1070位点,激活MAPK和PI3K/AKT通路。
- 靶向氨基酸979至1099结构域的抑制肽可抑制EGFR S1070磷酸化及耐药肿瘤活性。
核心结论
- NEK7通过磷酸化EGFR S1070位点促进肝细胞癌获得性仑伐替尼耐药。
研究设计与样本
- 建立获得性仑伐替尼耐药的类器官和肝细胞癌细胞系,采用激酶CRISPR-Cas9遗传筛选鉴定耐药基因。
主要发现
- NEK7增强肝细胞癌仑伐替尼耐药,NEK7敲低或敲除在获得性耐药细胞和类器官中显示抗肿瘤效应。
- NEK7结合EGFR并使其丝氨酸1070位点磷酸化,激活MAPK和PI3K/AKT信号通路。
- 靶向氨基酸979至1099结构域的抑制肽抑制EGFR S1070位点磷酸化,并治疗性抑制获得性仑伐替尼耐药肝细胞癌的抗肿瘤活性。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Lenvatinib is recognized as a first-line therapy for inoperable hepatocellular carcinoma (HCC) patients. Growing evidence indicates that lenvatinib resistance can be acquired in HCC cells via kinase rewiring. APPROACH AND RESULTS: We established acquired lenvatinib-resistant organoids and HCC cell lines. NIMA-related coiled-coil kinase 7 (NEK7) was identified as an HCC lenvatinib acquired resistance gene by kinase CRISPR-Cas9 genetic screen. Functional analyses demonstrate that NEK7 enhanced lenvatinib resistance in HCC, and NEK7 knockdown or knockout displays the antitumor effects in acquired lenvatinib HCC cells and organoids. Mechanistically, NEK7 binds to the endothelial growth factor receptor (EGFR), leading to the phosphorylation of EGFR specifically at the serine 1070 residue, which contributes to the activation of MAPK (mitogen-activated protein kinase) and PI3K/AKT (phosphoinositide 3-kinase/Akt) signaling pathways. Consistently, designed inhibitory peptides targeting the domain from amino acids 979 to 1099 were proven to inhibit phosphorylation of EGFR S1070 site and therapeutically inhibit antitumor activity of acquired lenvatinib resistance HCC. CONCLUSIONS: Our results unveil insights into the acquired lenvatinib resistance mechanism that NEK7 phosphorylates EGFR at S1070 to promote acquired lenvatinib resistance in HCC.
引用
- Huang Q, Wang W, Ge Q, et al. NEK7-induced phosphorylation of EGFR on serine 1070 drives the acquired lenvatinib resistance in hepatocellular carcinoma. Hepatology. 2025. PMID: 40694824. doi:10.1097/HEP.0000000000001474
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。